Leerink Partners, the health-care advisory firm, has continued a recent recruitment drive with hires from boutiques ...

Leerink downgraded 908 Devices (MASS) to Market Perform from Outperform with a price target of $4, down from $12. Though the firm still sees ...

Fintel reports that on November 13, 2024, Leerink Partners downgraded their outlook for 908 Devices (NasdaqGM:MASS) from ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...

Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) – Leerink Partnrs cut their FY2024 EPS estimates for Celldex ...

Beam Therapeutics (BEAM) stock gains as Leerink upgrades the biotech despite a fatality in a gene editing study, citing an ...

Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of Xencor in a ...

Leerink upgraded Beam Therapeutics (BEAM) to Outperform from Market Perform with a price target of $39, up from $27. The firm notes that prior to Tuesday’s BEAM-101 data in sickle-cell disease ...

Leerink assumed coverage of Mind Medicine with an Outperform rating and $20 price target The firm likes the emerging psychedelics space with increasing investment in clinical development across ...